Capitalbio Tech Nets over ￥800M in Pre-IPO Funding Round

According to VCBeat, recently, CapitalBio Tech, a Beijing-based molecular diagnostics product and service provider, announced that it completed a pre-IPO funding round of over 800 million yuan, led by Guangzhou Boyi Architectural Design Institute, an architectural design organization backed by Hong Kong-listed property developer Country Garden, with an injection of 400 million yuan. Other investors include Sinopec Capital, Meinian Onehealth, New Alliance Capital, Red Horse Investments Group, Xin Ding Capital, Friend Capital, and so on.

Proceeds from the latest round will be used to develop new products, expand the chip production line, further improve the company's pipelines in the fields of reproductive health, infection, cancer and so on, build the sales team and marketing, and further expand the overseas market. 

With the help of the financing, CapitalBio Tech will further consolidate its leading position in the field of genetic testing and biochips, and begin the application of IPO on the STAR Market.

Founded in August 2012, CapitalBio Tech is the industrialization platform of CapitalBio Corporation and the key enterprise of Tsinghua University in the field of life science and healthcare. Based on the next-generation biological detection technology, the company is engaged in the R&D, production, sales, and third-party medical laboratory services. It provides technical support and solutions for life science research, clinical diagnostics, new drug development, health management, judicial authentication, food safety at home and abroad.

At the same time, in response to the national health policy of "prevention first", CapitalBio Tech combines modern medicine with traditional Chinese medicine to build a big health business integrating health products, health management, medical rehabilitation and big data.

CapitalBio Tech's products include microarray and microfluidic chips as well as related instruments, software and databases, reagents, and consumables. It serves clients such as biomedical researchers and healthcare professionals.

Sinopec Group and Sinopec Corp. jointly established Sinopec Capital with 10 billion RMB initial paid-in registered capital. It strategically focuses on emerging industries including new energy, new material, advanced intelligent manufacturing, energy conservation and environmental protection，big data and artificial intelligence. 

Meinian Onehealth is a healthcare services provider. The company's core product is providing comprehensive health exams, such as physicals, blood tests, and electrocardiograms, but also offers other services such as health consultation and assessment.